Every article, presentation, spotlight, and news item we've tagged to Movement and Training.
Showing 25–40 of 40
Stem cell therapy demonstrates potential to address frailty in aging by restoring cellular repair capacity and tissue regeneration. This approach targets a fundamental mechanism of aging decline rather than managing symptoms.
Repeated measures of physical activity in community-dwelling older adults reveal that the protective association with dementia risk varies depending on timing relative to diagnosis, suggesting that activity patterns in the years immediately preceding cognitive decline may be more predictive than earlier lifetime activity. This finding reframes physical activity from a static risk factor into a dynamic variable whose relevance to dementia prevention depends on proximity to disease onset.
The wellness industry operates on infrastructure designed for episodic experiences rather than sustained behavioral change over decades. Longevity now requires systems-based approaches that embed healthy behaviors into everyday environments and social contexts, not temporary interventions delivered in specialized settings.
Blocking the ghrelin receptor improves muscle endurance and mitochondrial function in aging mice without affecting muscle mass or lifespan. Both genetic deletion and pharmacological inhibition restore markers of mitochondrial renewal, suggesting this pathway is a viable therapeutic target for age-related muscle decline.
Suppressing the ghrelin receptor (GHSR-1a) improves muscle function and reduces sarcopenia in aging mice through enhanced mitochondrial efficiency and altered muscle fiber composition. Pharmacological inhibition of this receptor produced similar benefits in older mice, suggesting a translatable approach to sarcopenia without extending lifespan.
Longeveron's Phase 2b trial of allogeneic mesenchymal stem cells in older adults with frailty demonstrated safety and measurable improvements in physical performance, including gait speed and functional measures. Results published in Cell Stem Cell validate a therapeutic approach targeting age-related functional decline rather than isolated disease markers.
Inhibiting the ghrelin receptor (GHSR-1a) improves muscle strength, exercise capacity, and mitochondrial function in aging mice, reducing sarcopenia markers without extending lifespan. Pharmacological inhibition via PF-5190457 replicates these effects and represents a translatable therapeutic approach.
Muscle fiber disorganization, quantified as a homeostatic dysregulation index, independently predicts mobility decline and reduced mitochondrial function in adults over 70, regardless of muscle mass. This establishes structural entropy as a measurable mechanism of skeletal muscle aging separate from loss of size alone.
Dizziness and vestibular dysfunction emerge as measurable precursors to cognitive decline and dementia, suggesting that dysfunction in balance and spatial orientation systems may reflect broader neurological compromise before overt cognitive symptoms manifest. This finding repositions a common but often-overlooked symptom as a potential biomarker for early neurological risk.
Atrogi has initiated human trials of ATR-258, an oral drug designed to preserve muscle mass during weight loss by mimicking exercise-induced metabolic effects. The approach addresses a critical gap in current obesity therapeutics: preventing muscle loss alongside fat loss, which is essential for maintaining strength, resilience, and functional independence in aging.
The Xplore Program is a fully remote summer fellowship designed to translate longevity interest into practical biotech experience through structured education and direct project placement with partner organizations. The program addresses a critical gap: making the pathway into longevity science explicit and accessible to talented individuals outside major biotech hubs.
Lifetime cognitive enrichment from childhood through late life is associated with a 38% reduced dementia risk and delays cognitive decline by 5–7 years. The protective effect accumulates across all life stages, with late-life engagement showing the strongest individual contribution to risk reduction.
Cognitive strategy interventions implemented through participatory action research enable people with neurocognitive disorders to maintain engagement in meaningful activities and preserve dignity. The approach leverages procedural memory—the capacity to retain learned motor and behavioral patterns—as a foundation for functional preservation despite cognitive decline.
Researchers have mapped 250 genes essential for human muscle fiber formation using a CRISPR screening platform, identifying previously unknown genetic drivers of muscle development and linking 41 of these genes to developmental muscle defects. This foundational knowledge directly informs understanding of sarcopenia and age-related muscle loss, where the same fusion mechanisms that fail in rare genetic disorders deteriorate progressively with age.
Digital engagement demonstrates bidirectional associations with successful aging in Chinese adults aged 60–75 over seven years, with baseline digital use predicting improvements in physical function, cognitive performance, and subjective well-being, while successful aging outcomes also predict sustained digital engagement. This longitudinal evidence suggests digital literacy and consistent technology use function as modifiable factors supporting multiple dimensions of aging outcomes.
Circulating stem cell count declines sharply after age 30, reducing tissue repair capacity and resilience. This decline correlates with recovery time, injury healing, and disease risk—making stem cell abundance a measurable predictor of healthspan independent of conventional longevity markers.
